UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study

Friis-Moller, N; Thiebaut, R; Reiss, P; Weber, R; Monforte, AD; De Wit, S; El-Sadr, W; ... DAD Study Grp, ; + view all (2010) Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. EUR J CARDIOV PREV R , 17 (5) 491 - 501. 10.1097/HJR.0b013e328336a150.

Full text not available from this repository.

Abstract

Aims HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complications, potentially increasing their risk of cardiovascular diseases (CVDs). Furthermore, exposures to some antiretroviral drugs seem to be independently associated with increased CVD risk. We aimed to develop cardiovascular risk-assessment models tailored to HIV-infected patients.Methods and results Prospective multinational cohort study. The data set included 22 625 HIV-infected patients from 20 countries in Europe and Australia who were free of CVD at entry into the Data collection on Adverse Effects of Anti-HIV Drugs Study. Using cross-validation methods, separate models were developed to predict the risk of myocardial infarction, coronary heart disease, and a composite CVD endpoint. Model performance was compared with the Framingham score. The models included age, sex, systolic blood pressure, smoking status, family history of CVD, diabetes, total cholesterol, HDL cholesterol and indinavir, lopinavir/r and abacavir exposure. The models performed well with area under the receiver operator curve statistics of 0.783 (range 0.642-0.820) for myocardial infarction, 0.776 (0.670-0.818) for coronary heart disease and 0.769 (0.695-0.824) for CVD. The models estimated more accurately the outcomes in the subgroups than the Framingham score.Conclusion Risk equations developed from a population of HIV-infected patients, incorporating routinely collected cardiovascular risk parameters and exposure to individual antiretroviral therapy drugs, might be more useful in estimating CVD risks in HIV-infected persons than conventional risk prediction models. Eur J Cardiovasc Prev Rehabil 17:491-501 (C) 2010 The European Society of Cardiology

Type: Article
Title: Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study
DOI: 10.1097/HJR.0b013e328336a150
Keywords: antiretroviral drugs, cardiovascular risk, HIV, prediction model, CORONARY-HEART-DISEASE, COMBINATION ANTIRETROVIRAL THERAPY, REVERSE-TRANSCRIPTASE INHIBITORS, HUMAN-IMMUNODEFICIENCY-VIRUS, MYOCARDIAL-INFARCTION, VASCULAR MORTALITY, DIABETES-MELLITUS, PROGNOSTIC MODEL, INDIVIDUAL DATA, BLOOD-PRESSURE
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute for Global Health > Infection and Population Health
URI: http://discovery.ucl.ac.uk/id/eprint/680407
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item